Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2004; 39(11): 657-661
DOI: 10.1055/s-2004-826037
Aktuelle Medizin und Forschung
© Georg Thieme Verlag KG Stuttgart · New York

Eine Innovation in der akuten Migränetherapie: CGRP-Rezeptorantagonisten

Innovative Treatment of Acute Migraine Pain with CGRP Receptor AntagonistsM.  K.  Herbert1 , P.  Holzer2
  • 1 Klinik und Poliklinik für Anästhesiologie der Universität Würzburg
  • 2 Institut für Experimentelle und Klinische Pharmakologie der Medizinischen Universität Graz
Dieser Beitrag wird von einem Editorial von H. G. Kress begleitet.
Further Information

Publication History

Publication Date:
02 November 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die durch Freisetzung vasoaktiver Neuropeptide, z. B. Calcitonin Gene-Related Peptide (CGRP), aus nozizeptiven perivaskulären Nervenfasern hervorgerufene neurogene Entzündung ist an der Pathogenese des akuten Migräneschmerzes beteiligt. Wie kürzlich gezeigt werden konnte, ist BIBN 4096 BS der erste CGRP-Rezeptorantagonist, der den akuten Migräneschmerz beim Menschen effizient mindert. Dies ist ein weiterer Hinweis dafür, dass das Neuropeptid CGRP mit zur Entstehung der akuten Schmerzattacke bei der Migräne beiträgt. Da BIBN 4096 BS keine vasokonstriktorischen Eigenschaften an meningealen und extrakraniellen Gefäßen besitzt, stellt dieser nichtpeptidische CGRP-Antagonist eine gute Alternative zur Behandlung der akuten Migräneattacke dar, insbesondere bei Patienten mit Kontraindikationen für Triptane und Ergotaminderivate.

Abstract

Neurogenic inflammation caused by the release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP) from nociceptive perivascular nerve fibres has been implicated in the development of acute migraine pain. It has recently been demonstrated that the CGRP receptor antagonist BIBN 4096 BS significantly reduces acute pain in migraine. This therapeutic efficacy provides further evidence for a critical role of CGRP in the pathophysiology of migraine. Given the apparent absence of vasoconstrictor activity both in meningeal and extracranial vessels, BIBN 4096 BS may provide an alternative for the treatment of migraine in those patients where triptans and ergotamine derivatives are contraindicated due to their side effects.

Schlüsselwörter

CGRP-Rezeptorantagonist - BIBN 4096 BS - Migräne - Neurogene Entzündung - Triptane

Key words

CGRP receptor antagonist - BIBN 4096 BS - migraine - neurogenic inflammation - triptans

Literatur

  • 1 Ferrari M D. Migraine.  Lancet. 1998;  351 1043-1051
    CrossrefPubMedGoogle Scholar
  • 2 May A, Goadsby P J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation.  J Cereb Blood Flow Metab. 1999;  19 115-127
    PubMedGoogle Scholar
  • 3 Ray B S, Wolff H G. Experimental studies on headache: pain sensitive structures of the head and their significance in headache.  Arch Surg. 1940;  41 813-856
    CrossrefPubMedGoogle Scholar
  • 4 Moskowitz M A. The neurobiology of vascular head pain.  Ann Neurol . 1984;  16 157-168
    CrossrefPubMedGoogle Scholar
  • 5 Olesen J. Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications.  Cerebrovasc Brain Metab Rev. 1991;  3 1-28
    PubMedGoogle Scholar
  • 6 Haan J, Terwindt G M, Ferrari M D. Genetics of migraine.  Neurol Clin. 1997;  15 43-60
    CrossrefPubMedGoogle Scholar
  • 7 Ophoff R A, Terwindt G M, Vergouwe M N, van Eijk R, Oefner P J, Hoffman S M, Lamerdin J E, Mohrenweiser H W, Bulman D E, Ferrari M, Haan J, Lindhout D, van Ommen G J, Hofker M H, Ferrari M D, Frants R R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.  Cell. 1996;  87 543-552
    CrossrefPubMedGoogle Scholar
  • 8 Ophoff R A, Terwindt G M, Frants R R, Ferrari M D. P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy.  Trends Pharmacol Sci. 1998;  19 121-127
    PubMedGoogle Scholar
  • 9 Terwindt G M, Ophoff R A, van Eijk R, Vergouwe M N, Haan J, Frants R R, Sandkuijl L A, Ferrari M D. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura.  Neurology. 2001;  56 1028-1032
    CrossrefPubMedGoogle Scholar
  • 10 Ebersberger A, Portz S, Meissner W, Schaible H G, Richter F. Effects of N-, P/Q- and L-type calcium channel blockers on nociceptive neurones of the trigeminal nucleus with input from the dura.  Cephalalgia. 2004;  24 250-261
    CrossrefPubMedGoogle Scholar
  • 11 Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck R V, Coenen H H, Diener H C. Brain stem activation in spontaneous human migraine attacks.  Nature Med. 1995;  1 658-660
    PubMedGoogle Scholar
  • 12 Bahra A, Matharu M S, Buchel C, Frackowiak R S, Goadsby P J. Brainstem activation specific to migraine headache.  Lancet. 2001;  357 1016-1017
    CrossrefPubMedGoogle Scholar
  • 13 Rasmussen B K, Olesen J. Migraine with aura and migraine without aura: an epidemiological study.  Cephalalgia. 1992;  12 221-228
    CrossrefPubMedGoogle Scholar
  • 14 Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory.  Brain. 1994;  117 199-210
    CrossrefPubMedGoogle Scholar
  • 15 Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine.  Ann Neurol. 1981;  9 344-352
    CrossrefPubMedGoogle Scholar
  • 16 Ebersberger A, Schaible H G, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache?.  Ann Neurol. 2001;  49 7-13
    CrossrefPubMedGoogle Scholar
  • 17 Woods R P, Iacoboni M, Mazziotta J C. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache.  N Engl J Med. 1994;  331 1689-1692
    CrossrefPubMedGoogle Scholar
  • 18 Gardner-Medwin A R. Possible roles of vertebrate neuroglia in potassium dynamics, spreading depression and migraine.  J Exp Biol. 1981;  95 111-127
    PubMedGoogle Scholar
  • 19 Moskowitz M A, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches.  Cerebrovasc Brain Metab Rev. 1993;  5 159-177
    PubMedGoogle Scholar
  • 20 Kaube H, Goadsby P J. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat.  Eur Neurol. 1994;  34 30-35
    PubMedGoogle Scholar
  • 21 Herbert M K, Holzer P. Die neurogene Entzündung. I. Grundlegende Mechanismen, Physiologie und Pharmakologie.  Anasthesiol Intensivmed Notfallmed Schmerzther. 2002;  37 314-325
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Herbert M K, Holzer P. Die neurogene Entzündung. II. Pathophysiologie und klinische Implikationen.  Anasthesiol Intensivmed Notfallmed Schmerzther. 2002;  37 386-394
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Williamson D J, Hargreaves R J. Neurogenic inflammation in the context of migraine.  Microsc Res Tech. 2001;  53 167-178
    CrossrefPubMedGoogle Scholar
  • 24 Lassen L H, Haderslev P A, Jacobsen V B, Iversen H K, Sperling B, Olesen J. CGRP may play a causative role in migraine.  Cephalalgia. 2002;  22 54-61
    CrossrefPubMedGoogle Scholar
  • 25 Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. Pharmacological profile of BIBN 4096 BS, the first selective small molecule CGRP antagonist.  Br J Pharmacol. 2000;  129 420-423
    CrossrefPubMedGoogle Scholar
  • 26 Moreno M J, Abounader R, Hebert E, Doods H, Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN 4096 BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.  Neuropharmacology. 2002;  42 568-576
    CrossrefPubMedGoogle Scholar
  • 27 Olesen J, Diener H C, Husstedt I W, Goadsby P J, Hall D, Meier U, Pollentier S, Lesko L M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.  N Engl J Med. 2004;  350 1104-1110
    CrossrefPubMedGoogle Scholar
  • 28 Tfelt-Hansen P, Block G, Dahlof C, Diener H C, Ferrari M D, Goadsby P J, Guidetti V, Jones B, Lipton R B, Massiou H, Meinert C, Sandrini G, Steiner T, Winter P B. Guidelines for controlled trials of drugs in migraine: second edition.  Cephalalgia. 2000;  20 765-786
    CrossrefPubMedGoogle Scholar
  • 29 Goadsby P J, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.  Ann Neurol. 1990;  28 183-187
    CrossrefPubMedGoogle Scholar
  • 30 May A, Goadsby P J. Substance P receptor antagonists in the therapy of migraine.  Expert Opin Investig Drugs. 2001;  10 673-678
    CrossrefPubMedGoogle Scholar
  • 31 Roon K I, Olesen J, Diener H C, Ellis P, Hettiarachchi J, Poole P H, Christianssen I, Kleinermans D, Kok J G, Ferrari M D. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.  Ann Neurol. 2000;  47 238-241
    CrossrefPubMedGoogle Scholar
  • 32 Goldstein D J, Wang O, Saper J R, Stoltz R, Silberstein S D, Mathew N T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.  Cephalalgia. 1997;  17 785-790
    CrossrefPubMedGoogle Scholar
  • 33 Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans?.  Trends Pharmacol Sci. 2000;  21 244-246
    CrossrefPubMedGoogle Scholar
  • 34 Herbert M K, Holzer P. Warum versagen Substance P(NK1)-Rezeptorantagonisten in der Schmerztherapie?.  Anaesthesist. 2002;  51 308-319
    CrossrefPubMedGoogle Scholar
  • 35 Durham P L. CGRP-receptor antagonists - a fresh approach to migraine therapy?.  N Engl J Med. 2004;  350 1073-1075
    CrossrefPubMedGoogle Scholar
  • 36 Goadsby P J, Hoskin K L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?.  Pain. 1996;  67 355-359
    CrossrefPubMedGoogle Scholar
  • 37 Goadsby P J, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT1B/1D) receptors.  Br J Pharmacol. 1997;  122 918-922
    CrossrefPubMedGoogle Scholar
  • 38 Ferrari M D, Roon K I, Lipton R B, Goadsby P J. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials.  Lancet. 2001;  358 1668-1675
    CrossrefPubMedGoogle Scholar
  • 39 Visser W H, Jaspers N M, de Vriend R H, Ferrari M D. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.  Cephalalgia. 1996;  16 554-559
    CrossrefPubMedGoogle Scholar
  • 40 Dodick D W. Triptans and chest symptoms: the role of pulmonary vasoconstriction.  Cephalalgia. 2004;  24 298-304
    CrossrefPubMedGoogle Scholar
  • 41 Diener H C, Brune K, Gerber W D, Göbel H, Pfaffenrath V. Behandlung der Migräneattacke und Migräneprophylaxe.  Dt Ärztebl. 1997;  94 3092-3102
    PubMedGoogle Scholar
  • 42 Tfelt-Hansen P, De Vries P, Saxena P R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.  Drugs. 2000;  60 1259-1287
    CrossrefPubMedGoogle Scholar

Prof. Dr. Michael K. Herbert

Klinik und Poliklinik für Anästhesiologie der Universität Würzburg ·

Oberdürrbacher Straße 6 · 97080 Würzburg

Email: herbert_m@klinik.uni-wuerzburg.de